Welcome to our dedicated page for Stereotaxis SEC filings (Ticker: STXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stereotaxis, Inc. filings document an operating medical-technology company focused on robotic systems and instruments for minimally invasive endovascular intervention. Recent Form 8-K reports record operating and financial results, product and regulatory information included in earnings materials, and material-event disclosures.
The company’s SEC record also includes a definitive proxy statement covering annual-meeting and shareholder voting matters, governance, executive compensation, and director elections. Capital-structure filings describe common stock, shelf registration use, and an at-the-market sales agreement for working capital, research and development, and commercialization of the company’s innovation pipeline.
Stereotaxis, Inc. reported first quarter 2026 results alongside major strategic and regulatory milestones. Revenue was $6.3 million, down from $7.5 million in the prior-year quarter, with systems revenue of $1.3 million and recurring revenue of $5.0 million.
Gross margin was 60%, and the company posted an operating loss of $6.0 million and net loss of $5.9 million. Adjusted operating expenses were $6.7 million, roughly flat versus the prior year, and negative free cash flow was $3.5 million. Stereotaxis ended March 31, 2026 with $14.6 million in cash and no debt.
The company highlighted U.S. FDA approval of its MAGiC robotically-navigated catheter in January and Synchrony digital operating room system in April, both now in commercial use. It also signed a definitive agreement to acquire Robocath, expanding its robotic platform. Stereotaxis expects double-digit revenue growth in 2026, total revenue above $40 million, and third- and fourth-quarter revenue each above $10 million, supported by manufacturing ramps for GenesisX and MAGiC.
Stereotaxis, Inc. agreed to acquire 100% of French robotics company Robocath through a Share Sale Agreement. The company will deliver initial consideration valued at $20.0 million in cash, Stereotaxis common stock based on $2.00 per share, or a mix, subject to closing adjustments.
The sellers may also receive up to $25 million in earnout payments tied to one FDA regulatory milestone and two commercial sales milestones. Part of the stock consideration may instead be delivered as pre-funded warrants, and total stock issued for upfront and milestone consideration is capped at 19.9% of shares outstanding before closing under NYSE American rules.
Stereotaxis will provide Robocath interim financing via monthly bonds initially expected to total about €1,300,000. Closing is targeted for July 2026, subject to debt restructuring, French regulatory clearance, absence of blocking legal orders or material adverse effects, and other customary conditions, with an outside end date of December 31, 2026.
Stereotaxis, Inc. Chief Financial Officer Kimberly R. Peery received a grant of stock options for 40,000 shares of common stock. The options carry an exercise price of $1.87 per share and expire on April 11, 2036, functioning as compensation rather than an open‑market purchase.
According to the vesting terms, 25% of the options vest one year after the grant date, with the remaining 75% vesting monthly over the next three years. Following this grant, Peery directly holds 340,750 derivative securities in total.
Stereotaxis, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The amendment adds the signature and consent of its independent registered public accounting firm, Ernst & Young LLP, and corrects an exhibit number designation.
The amendment does not update other disclosures and should be read together with the original filing. Ernst & Young issued an unqualified opinion on the consolidated financial statements and identified a single critical audit matter related to systems revenue recognition, focusing on contracts with multiple performance obligations and the allocation of transaction prices.
Stereotaxis, Inc. is calling shareholders to its 2026 Annual Meeting on May 14, 2026, at its St. Louis headquarters. Shareholders will vote to elect three Class I directors through 2029, ratify Ernst & Young LLP as 2026 auditor, and approve executive pay by a non-binding advisory vote.
Holders of 97,477,538 common shares and 21,008 Series A Convertible Preferred shares, representing an aggregate 121,182,983 votes as of March 16, 2026, may vote. The proxy describes a largely independent board with a lead independent director, committee structures, and an executive pay program that emphasizes long-term equity incentives, including a low $60,000 base salary for the CEO and performance-based awards.
Stereotaxis, Inc. files a replacement shelf registration that carries forward $79,639,304 of unsold securities under Rule 415(a)(6) as replacement registration for the prior registration declared effective June 6, 2023. The filing establishes a shelf for up to $100,000,000 of securities, including an at-the-market sales agreement previously sized at $50,000,000.
The prospectus states that upon effectiveness the remaining $42,139,304 available under the prior sales agreement will be included in the Sales Agreement prospectus forming part of this registration statement. Shares outstanding were 97,248,936 as of February 28, 2026, provided here as a context figure.
Stereotaxis, Inc. provides an annual overview of its robotic magnetic navigation business, highlighting products for electrophysiology and complex endovascular procedures. The company reports system backlog of approximately $9.1 million as of December 31, 2025, compared with $14.4 million as of December 31, 2024, noting potential variability in converting backlog to revenue due to long sales and installation cycles.
The report emphasizes expansion of the portfolio, including the GenesisX RMN system, Synchrony and SynX lab solutions, and proprietary MAGiC and MAGiC Sweep catheters, alongside the 2024 acquisition of Access Point Technologies EP, Inc. It also discusses broad global regulatory clearances, a diversified recurring-revenue base from disposables and service, and detailed risk factors such as supply-chain pressures, reliance on strategic partners, capital-raising needs, and the scheduled end of Johnson & Johnson catheter supply obligations on December 31, 2025.
Stereotaxis, Inc. reported strong growth for 2025, with revenue rising to $32.4 million, up from $26.9 million, driven by new robotic systems and recurring disposables and service revenue. Fourth-quarter revenue reached $8.6 million, a 36% increase year over year.
Full-year gross margin was 53%, and adjusted operating loss improved to ($9.3) million from ($12.4) million. The company ended 2025 with $13.4 million in cash and no debt. Management highlighted regulatory approvals and initial commercialization of the GenesisX robot and MAGiC catheter portfolio, while acknowledging manufacturing ramp challenges.
For 2026, Stereotaxis expects double-digit revenue growth, with annual revenue projected to surpass $40 million and lower cash use. The company is targeting higher manufacturing volumes, at least five active GenesisX programs, over $3 million of Synchrony digital suite revenue, and progress across its endovascular robotics and AI-enabled digital solutions.
Stereotaxis, Inc. director Arun S. Menawat reported receiving a new equity award in the form of restricted share units of the company’s common stock. On 01/02/2026, he was granted 46,948 shares of common stock at a stated price of $0, increasing his directly held beneficial ownership to 992,457 shares after the transaction.
The filing explains that each restricted share unit represents the right to receive one share of common stock. These units vest on the earliest of three events: the fifth anniversary of the award date, the date his service as a director on the board ends, or the occurrence of a Change of Control as defined in the award documents.